NCT05809336View on ClinicalTrials.gov

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

Inosine 0.2g orally 3 times/day

inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,

DRUG

PD-1/PD-L1 inhibitor ,chemotherapy/targeting

PD-1/PD-L1 inhibitor ± chemotherapy/targeting

Trial Locations (1)

100029

Qin li, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER

NCT05809336 - Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors | Biotech Hunter | Biotech Hunter